Tsvetana is a writer for Oilprice.com with over a decade of experience writing for news outlets such as iNVEZZ and SeeNews. U.S. energy investor Kimmeridge has offered to buy natural gas producer ...

Dec 16 (Reuters) - Activist investment firm Kimmeridge Energy Management has submitted a $6 billion offer to buy Ascent Resources, the Financial Times reported on Tuesday. The bid is the latest ...

Berenberg lowered the firm’s price target on Kenmare Resources (KMRPF) to 290 GBp from 300 GBp and keeps a Hold rating on the shares. Published first on TheFly – the ultimate source for real-time, ...

This course introduces participants to ways they can improve their time management skills by reducing time wasting behaviors and thinking patterns, and increasing organization. Participants will ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Liz Simmons is an education staff writer at Forbes Advisor. She has written about higher education and career development for various online publications since 2016. She earned a master’s degree in ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Somer G. Anderson is CPA, doctor of ...

The current DraftKings promo code offers new users $300 in bonus bets if their first bet of $5 or more wins. This latest DraftKings promo can be claimed by betting on any sport taking place today, ...

These top-rated backup services make it easy to create online and local copies of important files so you can retrieve them if disaster strikes. I've been testing PC and mobile software for more than ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. Membership (fee-based) Forbes Human Resources Council is an invitation-only, fee-based ...

GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...